PT - JOURNAL ARTICLE AU - Nyarko, Eric NY AU - Kumi, Justice AU - Ofori, Emmanuel K AU - Ateko, Richmond O. AU - Appiah, Michael AU - Adjei, Afua B. AU - Dodoo, Derrick N.D. AU - Amoah, Broderick Yeboah AU - Crabbe, Sandra ANA AU - Amakye, Ebenezer K AU - Amanquah, Seth D AU - Obirikorang, Christian AU - Asare-Anane, Henry TI - CoViD-19 rRT-PCR Testing Capacity in Ghana; Indications of Preparedness for Marburg virus Outbreak? AID - 10.1101/2022.10.11.22280953 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.11.22280953 4099 - http://medrxiv.org/content/early/2022/10/11/2022.10.11.22280953.short 4100 - http://medrxiv.org/content/early/2022/10/11/2022.10.11.22280953.full AB - Introduction Ghana, as of July 2022, has had 168,350 Real-Time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR)-confirmed cases of CoViD-19 infections and 1,458 deaths. Besides, 2 cases of Marburg virus diseases (MVD) were confirmed in the country within the same month. Both CoViD-19 and MVD require rRT-PCR for diagnosis, however, rRT-PCR facilities are scarce in Ghana – especially, hitherto, the CoViD-19 pandemic. The objectives of this study were to assess the current testing capacity of CoViD-19 rRT-PCR in Ghana, and to make some recommendations in case of an MVD outbreak, or recurrence of the CoViD-19 pandemic.Methods The study was cross-sectional. Questionnaires were administered to 100 health professionals actively involved in the testing cycle of CoViD-19 across rRT-PCR testing institutions. Responses with regards to CoViD-19 rRT-PCR testing, biosafety, and relationship with Surveillance Outbreak Response Management and Analysis System (SORMAS), PanaBios and Zipline, were obtained for 2020-through-2022. The responses were analyzed with Microsoft Excel office-365 and SPSS v.23.Results Thirty-five (35) of the 53 testing institutions were in the Greater Accra Region, but none in seven (7) regions of the country. Many (49%) were privately owned. Nine (9) different professionals were involved in rRT-PCR testing. The testing institutions increased from 2 (in March 2020) to 53 by June-ending 2022, and most (90%) had Biosafety Cabinet class II (BSCII). PPEs were inadequate between march and June, 2020 (25%), but enough (100%) by June 2022. Zipline, SORMAS, and PanaBios, respectively, saw transactions from 28%, 81%, and 77% of the institutions.Conclusion Ghana is adequately resourced for recurrence of CoViD-19, or any MVD outbreak, in terms of diagnosis with rRT-PCR. However, the country needs redistribution of these testing resources, expand the services of Zipline and SORMAS, satisfy additional biosafety requirements for MVD testing and equip over 180 GeneXpert facilities to help in accessible and affordable testing.What is already known on this topic It is known that there are CoViD-19 PCR testing laboratories (outside the public health system) and a drone service company available now in Ghana for transport of medical supplies, and samples especially in the heat of the CoViD-19 pandemic – called Zipline.What this study adds The findings of this study detail the number of these testing laboratories and the drone company - including their presence or sites across the 16 regions of Ghana. It also illuminates on the biosafety cabinet classes and other PPE status of the country, professionals involved in direct rRT-PCR testing, the benefits of SORMAS and Zipline in managing the pandemic, cost of consumables and tests within the 2 years of the pandemic, and what should be done(now) to make Ghana prepared for other infectious viral outbreaks, like the Marburg virus.How this study might affect research, practice or policy The study, based on its findings, recommend the redistribution of the rRT-PCR testing infrastructure across the country, expand the services of Zipline and SORMAS, employ the use of existing Cepheid GeneXperts in its rRT-PCR testing, and upgrade its biosafety cabinet class requirements to the level able to contain other possible outbreaks like the hemorrhagic the Marburg virus, in terms of testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsrRT-PCRReal-Time Reverse Transcription-Polymerase Chain ReactionCoViD-19SARS – COV-2 Disease 2019MVMarburg VirusMVDMarburg Virus DiseaseNAATNucleic acid amplification testingPPSPositive Pressure SuitGHSGhana Health ServiceWHOWorld Health OrganizationSORMASSurveillance Outbreak Response Management and Analysis SystemTATAverage turn-around-time per test per patientCDCCentre for Disease Control and Prevention, USABSCBiosafety CabinetPPEPersonal Protective Equipment